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Two placebo-controlled trials have shown that early administration of intravenous recombi-
nant tissue plasminogen activator (rt-PA) after ischemic stroke improves outcomes up to
4.5 h after symptoms onset; however, six other trials contradict these results.We also know
from analysis of the pooled data that benefits from treatment decrease as time from stroke
onset to start of treatment increases. In addition to time, another important factor is patient
selection through multimodal imaging, combining data from artery status, and salvageable
tissue measures. Nonetheless, at the present time randomized controlled trials (RCTs)
cannot demonstrate any beneficial outcomes for neuroimaging mismatch selection after
4.5 h from symptoms onset. By focusing on cases of large arterial occlusion, we know that
recanalization is crucial, so endovascular treatment is an approach of interest. The use of
intra-arterial thrombolysis was tested in two small RCTs that demonstrated clear benefits in
terms of higher recanalization and also in clinical outcomes. But a new paradigm of stroke
treatment may have begun with mechanical thrombectomy. In this field, Merci devices
have been overtaken by fully deployed closed-cell self-expanding stents (stent-retrievers
or “stent-trievers”). However, despite the high rate of recanalization achieved with stent-
retrievers compared with other recanalization treatments, the use of these devices cannot
clearly demonstrate better outcomes. Thus, futile recanalization occurs when successful
recanalization fails to improve functional outcome. Recently, three RCTs, namely synthesis,
IMS-III, and MR-rescue, have not been demonstrated any clear benefit for endovascular
treatment. Most likely, these trials were not adequately designed to prove the superiority
of endovascular treatment because they did not use optimal target populations, vascular
status was not evaluated in all patients, relatively high rates of patients did not have enough
mismatch, time from baseline neuroimaging to recanalization were too long or the devices
used are now obsolete relative to stent-retrievers. Several RCTs currently underway are
trying to determine whether bridging therapy is more effective than intravenous treatment
and if mechanical thrombectomy is more effective than best medical treatment in patients
ineligible for intravenous thrombolysis.
Keywords: mechanical thrombectomy, ischemic stroke, stent-retriever, endovascular clinical trials, futile
recanalization, reperfusion
INTRODUCTION
Intravenous recombinant tissue plasminogen activator (rt-PA) is
the only approved treatment for acute ischemic stroke within 4.5 h
from symptoms onset, as supported by two placebo-controlled
trials (1, 2), meta-analyses (3–5), and observational studies (6, 7).
However, many patients are still left undertreated due to the fact
of factors such as an unknown onset time for the stroke, the nar-
row time window, a lack of awareness that stroke has occurred
or the high number of exclusion criteria for currently approved
treatments.
Several strategies have been developed in order to increase the
number of treated patients. The EPITHET and DEFUSE studies
suggest that multimodal neuroimaging may help to select patients
with salvegeable brain tissue up to 6 h after stroke onset (8, 9).
EPITHET was a prospective, randomized, double blind, placebo-
contolled, and phase II trial that tested alteplase between 3 and 6 h
after stroke onset in patients who were imaged with serial echo-
planar MRI at baseline and at 3–5 days after therapy. The primary
outcome measure was attenuation of infarct growth. Although
there was a non-significant trend toward a positive result, in the
subgroup of patients with mismatch alteplase was significantly
associated with increased reperfusion and improved clinical out-
comes (8). The method of measuring this mismatch volume was
the standard volumetric technique in which volumes were cal-
culated by simple subtraction. A more precise method based on
coregistration of DWI and PWI images showed larger mismatch
volumes and significant attenuation of infarct growth by alteplase
(9). DEFUSE, an open-label study of intravenous alteplase from
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3 to 6 h from stroke onset, showed that the occurrence of early
reperfusion led to good clinical outcomes in patients with target
mismatch. This mismatch profile was defined as a PWI lesion that
was 10 ml or more and 120% or more of the DWI lesion. DEFUSE
also identified an MRI pattern called “malignant profile,” charac-
terized by a DWI lesion 100 ml or more and/or a large PWI lesion
of 100 ml or more with 8 s or longer of T max delay. The tar-
get profile appears to identify patients with an especially robust
clinical response rate (67%) after early reperfusion whereas the
malignant profile is strongly associated with reperfusion-related
brain hemorrhage.
Besides alteplase, new thrombolytic drugs like tenecteplase and
desmoteplase may potentially be safer in extended windows up
to 6 or 9 h from symptoms onset in patients with salvageable
brain tissue. Tenecteplase is a third generation point mutation
tissue plasminogen activator that has a longer half-life, greater
binding affinity for fibrin and better resistance to inactivation by
the endogenous inhibitor PAI-1 compared to alteplase. In a non-
randomized study of ischemic stroke patients with CT perfusion
mismatch within 3–6 h of symptoms onset, tenecteplase at low
dose (0.1 mg/kg) appeared to be superior to alteplase (10). A poste-
rior randomized phase IIb study using a similar design found that
moderate (0.25 mg/kg) and low doses (0.1 mg/kg) of tenecteplase
yielded significantly better patient outcomes than standard doses
of alteplase. Tenecteplase was associated with increased reper-
fusion, early neurological improvement, and improved 3 month
functional outcome with the higher dose without an increase in
ICH rate (11).
Desmoteplase is a thrombolytic drug extracted from the saliva
of vampire bats. It is more selective for fibrin and has not been
to shown to have any deleterious effect on the blood brain barrier
compared to alteplase. Two promising phase II studies, DIAS and
DEDAS, demonstrated increased reperfusion and strong trends to
improved outcome with desmoteplase compared with placebo in
acute stroke patients using imaging selection with CT perfusion or
multimodal MRI treated within 3–9 h from stroke onset (12, 13).
These trial results, however, were not confirmed in DIAS-2 (14).
The main reasons for this neutral effect might lie in the lack of
standardized imaging assessment of penumbra and the substan-
tial number of patients without main cerebral arterial occlusions.
A pooled analysis of DIAS, DEDAS, and DIAS-2 results showed
that patients with proximal vessel occlusion or high grade steno-
sis had greater mismatch and positive response to desmoteplase
compared to placebo (15). Current ongoing DIAS-3 and DIAS-4
trials were designed to correct the errors of DIAS-2 (16).
A critical point to obtain a favorable risk/benefit effect of
extended intravenous thrombolysis is the existence of an arter-
ial occlusion. A post hoc study of pooled data from EPITHET and
DEFUSE showed a benefit for intravenous tPA over placebo on
infarct growth attenuation only in patients with arterial occlusion
(17). Regarding occlusion site, the more distally the occlusion is
located, the higher the likelihood of recanalization. By using tran-
scranial Doppler, complete recanalization at 2 h after intravenous
rt-PA bolus has been shown in 44, 29, and 10% of cases involv-
ing distal middle cerebral artery, proximal middle cerebral artery,
and terminal internal carotid artery, respectively (18). However,
some adjunctive strategies like sonothrombolysis appear to be
safe and obtain higher complete recanalization rates after intra-
venous thrombolysis. The CLOTBUST-HF study (19) included
20 patients, with 14 of the 20 (70%) occlusions occurring in the
middle cerebral artery (12 of these 14 in the proximal middle
crebral artery), 3 more (15%) in the terminal carotid artery, and
the remaining 3 (15%) in the verebral artery. Rates of complete
recanalization at 2 h were 8 out of 20 (40%), all of them MCA
occlusions (i.e., 8 or 57% of the 14).
Due to the fact that the effect of tPA is limited in proximal occlu-
sions, other approaches have been tested to open the occluded
vessels. Endovascular treatment may be an option to increase
recanalization and therefore effective reperfusion rates. A num-
ber of trials have tested this hypothesis (Table 1). Endovascular
treatment covers two different modalities: intra-arterial admin-
istration of thrombolytic drugs, mainly rt-PA and urokinase, and
mechanical thrombectomy. Both modalities have the disadvantage
over intravenous approaches that they require additional time to
be started and are available only in specialized centers. However,
the first modality achieves benefits not only because it delivers
the drug just into the clot but also from the mechanical effect
of the catheter. The PROACT II trial was the first trial to show
the benefit of intra-arterial pro-urokinase compared to placebo.
Intracranial hemorrhage with neurological deterioration within
24 h occurred in 10% of pro-urokinase patients and 2% of con-
trol patients (p= 0.06). All symptomatic intracranial hemorrhages
occurred in patients with a baseline NIHSS score of 11 or higher
(20). Thereafter, the interventional management of stroke (IMS)
I and II trials suggested the feasibility and safety of a bridging
intra-arterial/intravenous approach compared with intravenous
tPA alone. However, the proportion of patients with good clini-
cal outcome (mRS 0–2) at 3 months was only slightly superior in
IMS I and II (43 and 46%) compared with patients treated with
intravenous tPA in the NINDS trial (39%), although the differ-
ences were higher compared with the NINDS placebo subgroup
(28%) (21, 22). This treatment modality has since been over-
taken by mechanical thrombectomy and in particular by thrombus
retrieval.
Mechanical approaches compared to intra-arterial pharmaco-
logical therapy are associated with greater technical difficulty, the
potential development of vasospasm, vessel dissection, perforation
or rupture, and distal embolization into previous unaffected terri-
tories due to fragmented thrombus. The MERCI® device achieved
complete recanalization in 48% of acute ischemic stroke patients
with large arterial occlusions treated within the first 8 h from stroke
onset (24). The MERCI trial (Table 1) included a large number of
patients who were not eligible for intravenous tPA. Their results
were comparable with the results of PROACT-II (20) and IMS-II
(23). Conversely, mortality was higher in the MERCI trial in accor-
dance with the differences between populations. Arterial recanal-
ization was independently associated with good outcome (mRS≤2
at 3 months), while the absence of recanalization was associated
with mortality. Although the recanalization rate with mechanical
thrombectomy was similar to that for intra-arterial thrombolysis,
only 25% of MERCI patients achieved a good functional out-
come. In the Multi MERCI trial (25) (Table 1), investigators used
a new generation of MERCI® devices (L5 Retriever) in patients
with large-vessel stroke within 8 h of symptoms onset. Regarding
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Table 1 | Baseline stroke severity and outcome variables in the main reperfusion trials carried out before the development of stent-retrievers.
n Baseline
NIHSS
Successful
recanalization (%)
(TIMI 2–3)
mRS 0–2 at
90 days (%)
90-day
mortality (%)
sICH (%)
Intravenous thrombolysis
Pooling analysis of phase IV trials within 6 h
(tPA groups) (4)
1391 11 NA 49 13 5–9b
Pooling analysis of phase IV trials within 6 h
including IST-3 (tPA groups) (5)
3548 – NA 46 19 7b
Endovascular treatment
PROACT II (20) 121 17 66 40 25 10
IMS (21) 62 18 56 43 16 6
IMS-II (23) 55 19 58 46 16 10
MERCI (24) 141 20 48a/60 28 44 8
Multi MERCI (25) 164 19 55a/68 36 34 10
Penumbra (26) 125 18 82 25 33 11
Control groups
Pooling analysis of phase IV trials within 6 h
(placebo groups)
1384 11 NA 44 15 1.1a
PROACT-II (control group) 59 17 18 25 27 2
aDevice alone.
bParenchimal hematoma type II. sICH, symptomatic Intra-cerebral Hemorrhage; tPA, tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National
Institutes of Health Stroke Scale.
safety, no differences were seen in the rates of intracranial hemor-
rhage or clinically significant procedural complications between
those patients treated with intravenous tPA and those who were
not. Another single-center study obtained similar findings (27).
A new thrombectomy system was used in the Penumbra Trial,
designed to evaluate the safety and effectiveness of the Penum-
bra thrombo-aspiration device (26) (Table 1) in patients with
acute ischemic stroke within the 8 h from symptoms onset with
NIHSS≥8 and angiograhic occlusion. Procedural events occurred
in 12.8% of cases, with 2.4% considered serious. In this study, 25%
of patients achieved a modified Rankin Scale score of ≤2. Taken
together, these findings suggest that the Penumbra System obtains
higher revascularization rates than those reported for the MERCI®
device. The safety profile of the Penumbra System is also favorable
but despite this, considering the high revascularization rate, the
clinical functional outcome was lower than expected. The absence
of imaging-guided patient selection and historical control design
in these studies may render elusive a definitive conclusion on long-
term outcome. Therefore, the effect of revascularization on clinical
functional outcome should only be evaluated by a controlled trial
in well-selected patients.
Recently, a new paradigm of more promising stroke treatment
has begun with the use of fully deployed closed-cell-expanding
stents (stent-retrievers or “stent-trievers”), which achieve recanal-
ization rates of up to 90%. However, improvement of revascu-
larization has not been paralleled by favorable responses in clin-
ical outcome. DEFUSE 2 (28) results for which have only been
published recently, was a prospective cohort study that enrolled
patients to have endovascular treatment within 12 h from symp-
toms onset to establish whether the patient had an MRI baseline
profile (target mismatch) predictive of salvageable tissue. A total
of 46 out of 78 (59%) patients with target mismatch and 12
out of 21 (57%) patients without target mismatch had reperfu-
sion after endovascular treatment. The adjusted odds ratio (OR)
for favorable clinical response associated with reperfusion was
8.8 [95% confidence interval (CI) 2.7–29.0] in the target mis-
match group and 0.2 (0.0–1.6) in the no target mismatch group
(p= 0.003 for difference between ORs). Reperfusion was associ-
ated with increased good functional outcome at 90 days (OR 4.0;
95% CI 1.3–12.2) in the target mismatch group, but not in the no
target mismatch group (1.9; 0.2–18.7). Thus, this trial showed
that target mismatch patients who had early reperfusion after
endovascular treatment had more favorable clinical outcomes.
No association between reperfusion and favorable outcomes was
present in patients without target mismatch.
In the overview that follows, we will analyze the limitations
of previous research and discuss future trial designs and as well as
the prospects for endovascular treatment for acute ischemic stroke
patients.
ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC
STROKE
WHAT HAVE WE LEARNED?
Recanalization continues to be one of the most powerful predictors
of successful outcome and is used as a surrogate of efficacy in acute
stroke RCTs. In a formal meta-analysis (29) involving a total of
2066 patients, reported recanalization rates categorized according
to the received intervention were spontaneous in 24.1% of cases,
46.2% after intravenous thrombolysis, 63.2% after intra-arterial
thrombolysis, 67.5% after combined intravenous-intra-arterial,
and 83.6% after mechanical thrombectomy. Clinical outcome cat-
egorized by as either success or failure in achieving recanalization
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was available from 998 patients. Good functional outcomes at
3 months were more frequent in recanalized vs. non-recanalized
patients with OR of 4.43 (95% CI 3.32–5.91). Three-month mor-
tality was reduced in recanalized patients (OR 0.24; 95% CI
0.16–0.35). Rates of symptomatic hemorrhagic transformation
did not differ between the two groups (OR 1.11; 95% CI 0.71–
1.74). These findings thus suggest that recanalization is an appro-
priate biomarker of therapeutic activity in early phase trials of
revascularization therapies in acute ischemic stroke.
Although arterial recanalization and subsequent reperfusion
should allow the restoration of brain function when it is done
early after ischemic stroke, this often fails. This futile recanalization
has been related to multiple downstream embolization, the non-
reflow phenomenon caused by blockage of microcirculation or
fast recruitment of ischemic tissue into infarction before recanal-
ization. Furthermore, reperfusion can be deleterious, through
brain–blood barrier disruption resulting in massive brain edema
or hemorrhagic transformation (30). Specifically, Hussein et al.
(31) in a multicentre study observed futile recanalization in 49% of
patients who received endovascular treatment for acute ischemic
stroke. Age>70 years (OR 4.4; 95% CI 1.9–10.5) and initial NIHSS
from 10 to 19 (OR 3.8; 95% CI 1.7–8.4; p< 0.001) emerged as
independent predictors of futile recanalization.
STENT-RETRIEVERS
As noted above, removable cerebral stents and clot retriever devices
referred to as stent-retrievers are a promising strategy to rein-
force mechanical thrombectomy. These devices achieve high rates
of recanalization and avoid the hemorrhagic complications asso-
ciated with the use of antithrombotic drugs needed when an
angioplasty and permanent stenting is used to achieve arterial
recanalization (32).
Retrospective non-controlled non-randomized studies
The first reported cases dealt with permanent placement of open-
cell self-expanding stents to recanalize embolic intracranial artery
occlusions by compressing the occluding thrombus represented
a big step forward in mechanical thrombectomy (33, 34). Mul-
tiple small case series reporting the results of the use of stent-
trievers have been published. Most of them showed high rates of
recanalization and outcome rates comparable with those reported
in intravenous thrombolysis trials. In general, patients treated
with these devices had higher NIHSS and were treated later than
patients treated with intravenous thrombolysis (35–57) (Table 2).
Prospective controlled studies
The solitaire flow restoration thrombectomy for acute revascular-
ization (STAR) was a prospective, multicentre, single-arm study
of mechanical thrombectomy using the Solitaire device (58) that
included 202 patients with a median basal NIHSS score of 17. Suc-
cessful recanalization was achieved in 79.2% of patients and favor-
able neurological outcome in 57.9%. Procedure-related complica-
tions occurred in 7.4%, intracranial hemorrhagic transformation
of some sort occurred in 18.8%,with 1.5% being symptomatic,and
mortality at 3 months occurred in 6.9%. A similar study was con-
ducted with the TREVO stent-retriever. The Trevo® study (59) was
a prospective, multicentre, and single-arm study in acute stroke
patients in which a total of 60 patients were enrolled. A TICI 2b-
3 was achieved in 78.3%. At 90 days, 55% of the patients had a
favorable neurological outcome (mRS 0–2) and 20% had died.
Patients with successful recanalization (TICI 2a, 2b, and 3) had
a 60% rate of good neurological outcome at day 90 (mRS 0–2),
whereas no patient without recanalization had a mRS 90< 3. The
overall rate of symptomatic intra-cerebral hemorrhage according
to the SITS-MOST criteria was 5% (3/60) (Table 2).
Prospective randomized controlled studies
SolitaireTM AB/FR and Trevo® were compared with the standard
predicate mechanical thrombectomy device, the Merci Retrieval
System, in two controlled randomized trials (SWIFT and TREVO-
2) to test the potential superiority of stent-retrievers. SWIFT
(60) was a randomized, parallel-group, non-inferiority trial that
randomly allocated 58 patients to the Solitaire group and 55
patients to the Merci group. The primary endpoint was partial
or complete recanalization (thrombolysis in myocardial ischemia,
TIMI 2 or 3) without symptomatic intra-cerebral hemorrhage,
assessed by an independent CoreLab, which was masked to study
assignment. Primary analysis was done by intention to treat. The
primary efficacy outcome was achieved more often in the Soli-
taire group than in the Merci group (61 vs. 24%; difference 37%
[95% CI 19–53], OR 4.87 [95% CI 2.14–11.10]; p non-inferiority
<0.0001, p superiority= 0.0001). More patients had 3 months
good neurological outcome in the Solitaire group than in the
Merci group (58 vs. 33%; difference 25% [95% CI 6–43], OR
2.78 [95% CI 1.25–6.22]; p non-inferiority= 0.0001, p superior-
ity= 0.002). Ninety-day mortality was lower in the Solitaire group
(17 vs. 38%; difference−21% [95% CI−39 to−3], OR 0.34 [95%
CI 0.14–0.81]; p non-inferiority= 0.0001, p superiority= 0.02).
These findings confirm that Solitaire achieves better angiographic
results and clinical outcomes than does the Merci Retrieval System.
TREVO 2 trial (61) was an open-label randomized controlled trial
that included patients aged from 18 to 85 years with confirmed
large-vessel occlusion stroke and NIHSS score from 8 to 29 within
8 h from symptoms onset. Randomization was stratified by age
(≤68 vs. 69–85) and NIHSS scores (≤18 vs. 19–29). The primary
efficacy endpoint was thrombolysis in cerebral infarction (TICI)
scores ≥2 assesed by an ummasked CoreLab. The primary safety
endpoint was a composite of procedure-related adverse events.
Analyses were done by intention to treat. The TREVO 2 trial ran-
domly allocated 88 patients to the Trevo group and 90 patients to
the Merci group. Seventy-six patients (86%) in the Trevo group
and 54 (60%) in the Merci group met the primary endpoint (OR
4.22; 95% CI 1.92–9.69; p superiority <0.0001). Incidence of
the primary safety endpoint did not differ between groups [13
(15%) patients in Trevo group vs. 21 (23%) in the Merci group;
p= 0.1826]. However, vessel perforations were almost 10 times
more common with Merci devices (10%) than with the Trevo
retriever (1%; p= 0.0182). Notably, these perforations did not
seem to have high clinical relevance, since the rates of symp-
tomatic intracranial hemorrhages and periprocedural mortality
were similar in the two groups (Table 2).
A single-center, prospective study on 33 patients showed no
significant differences between the Trevo and Solitaire stent-
retrievers (62).
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Table 2 | Comparision of baseline stroke severity and outcome variables in studies using stent-retrievers.
Author/year n Baseline NIHSS
median or
mean±SD
Successful
recanalization (%)
(TIMI 2–3)/(TICI 2b-3)
mRS 0–2 at
90 days (%)
90-day
mortality (%)
sICH (%)
Retrospective non-controlled non-randomized studies
Castaño et al. (54)b 1 23 100 100 mRS 3 0 0
Suh et al. (35)b 1 15 100 – – 0
Castaño et al. (36) 20 19 90 45 20 10
Roth et al. (44) 22 19.4±5.7 90.9 50 18.1 9
Venker et al. (46) 10 15.6±5.3 100 – – 0
Cohen et al. (37) 6 >17 100 100 0 0
Rohde et al. (43) 10 19 100 60 (30 days) 30 20
Stampfls et al. (45) 18 21±6.7 88.8 33,3 27.7 16.6
Wehrschvetz et al. (47) 11 16±4.7 18 30 9 0
Miteff et al. (48) 26 – 96 42 19 10
Costalat et al. (53) 50 15 84 54 12 2
Park et al. (52) 8 – 100 – – 0
Pérez et al. (42)b 1 10 100 100 (30 days) – 0
Kim et al. (34) 14 10 78.6 57.1 – 7.1
Cohen et al. (38) 17 >12 100 88.2 at month – 11.8
Machi et al. (39) 56 16 89.2 46.4 discharge 7.1 1.7
Möhlenbruch (41) 25 – 88 – – 12
Castro Alfonso (48) 21 17±6.36 90.1 61.9 9.5 14.2
Menon et al. (51) 40 – 85.7 57.1 14.3 –
San Roman et al. (50)a 60 18 86.7 45 28 12
Mpotsaris et al. (56) 26 16 88 38 7.6 –
Dávalos et al. (55) 141 18 85 55 20 4
Mendonça et al. (40) 13 19 77 30 30 0
Prospective studies with independent evaluation
STAR (57) 202 17 79.2 57.9 6.9 1.5
TREVO (58) 60 78.3 55 20 5
Prospective randomized crontrolled studies
SWIFT (Solitaire) (59) 58 18 61 58 17 2
55 18 24 33 38 11
TREVO-2 (Trevo) (60) 88 19 86 40 33 7
90 18 60 22 24 9
sICH, symptomatic intra-cerebral hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
aProspective study.
bSingle case reports.
The results of these trials were encouraging and support the use
of stent-retrievers in prospective trials of endovascular treatment
against medical treatment alone.
CONTROLLED TRIALS OF ENDOVASCULAR TREATMENT
Three randomized clinical trials (IMS-III, SYNTHESIS, and MR-
RESCUE) (63–65) designed to prove the superiority of endovas-
cular treatment compared to intravenous rt-PA in acute ischemic
stroke failed to demonstrate any benefits. We briefly describe the
main characteristics and results of these trials, and point out the
weaknesses that probably determined the negative results.
The IMS-III (63) was a randomized, parallel-arm trial com-
paring intravenous tPA followed by endovascular treatment with
intravenous tPA alone in patients with acute ischemic stroke within
3 h from symptoms onset. The angiographic procedure had to
begin within 5 h and be completed within 7 h after stroke onset.
The trial intended to enroll 900 subjects to ensure adequate statis-
tical power to detect an absolute 10% difference in the percentage
of patients with good outcome (mRS 0–2) at 3 months. After 656
patients were randomized (434 participants to endovascular ther-
apy and 222 to intravenous tPA alone), the study was prematurely
stopped based on the pre-specified criterion for futility. The pro-
portion of patients with a modified Rankin score of 2 or less at
90 days did not differ significantly according to treatment (40.8%
with endovascular therapy and 38.7% with intravenous tPA alone;
absolute difference, 1.5 percentage points; 95% CI−6.1 to 9.1, after
adjustment for the baseline NIHSS score. There were no significant
differences between the two treatment arms in the pre-defined
subgroups of patients with a NIHSS score ≥20 (6.8 percentage
points; 95% CI, −4.4 to 18.1) and ≤19 (−1.1 percentage point;
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95% CI−10.8 to 8.8). Both groups showed similar mortality rates
at 90 days (19.1 and 21.6%, respectively; p= 0.52) and sympto-
matic intra-cerebral hemorrhage within 30 h after initiation of
tPA (6.2 and 5.9%, respectively; p= 0.83).
In the SYNTHESIS trial (64), 362 patients with acute ischemic
stroke of less than 4.5 h after symptoms onset were 1:1 randomly
allocated to receive intravenous tPA or endovascular therapy
(intra-arterial thrombolysis with tPA, mechanical clot disruption
or retrieval, or a combinaton of these approaches) within <6 h
from onset. Primary outcome was survival free of disability at
3 months, defined as modified Rankin score 0–1. The median time
from stroke onset to start of treatment was 3.75 h for endovascular
therapy and 2.75 h for intravenous tPA (p< 0.001). Good primary
outcome was found in 30.4% of patients in the endovascular treat-
ment group and in 34.8% in the intravenous group (OR adjusted
for age, sex, stroke severity, and atrial fibrillation status at baseline
0.71; 95% CI 0.44–1.14; p= 0.16). Symptomatic intracranial hem-
orrhage within 7 days occurred in 6% of patients in each group;
there were no differences between groups in the rate of other seri-
ous adverse events or mortality. Subgroup analysis suggested that
the lack of superiority of endovascular therapy was not explained
by the time delay to endovascular treatment, stroke subtype, or
center. Importantly, the demonstration of vessel occlusion was not
a precondition for inclusion in this trial and the use of mechani-
cal thrombectomy devices was limited to Solitaire in 18 patients,
Penumbra in 9, Trevo in 5, and Merci in 5.
The MR RESCUE trial (65) was designed to study whether brain
imaging could identify patients who were most likely to benefit
from therapies for acute ischemic stroke and whether endovascu-
lar thrombectomy improved clinical outcome. The trial included
patients within 8 h after the onset of large-vessel, anterior circula-
tion strokes that were randomly assigned to undergo mechanical
embolectomy (Merci retriever or Penumbra System) or medical
treatment. Randomization was stratified according to whether the
patient had a favorable penumbral pattern (substantial salvageable
tissue and small infarct core) or a non-penumbral pattern (large
core or small or absent penumbra). Among 118 eligible patients,
the mean time to enrollment was 5.5 h, and 58% had a favor-
able penumbral pattern. Revascularization in the embolectomy
group was achieved in 67% of patients, 90-day mortality was 21%
and the rate of symptomatic intracranial hemorrhage was 4%; no
rate differed across groups. Among all patients, the mean score
on the modified Rankin score was equal in the embolectomy and
standard of care groups (3.9 vs. 3.9, p= 0.99). Embolectomy was
not superior to standard of care in patients with either a favor-
able penumbral pattern (mean score 3.9 vs. 3.4; p= 0.23) or a
non-penumbral pattern (mean score 4.0 vs 4.4; p= 0.32). There
was no interaction between the pretreatment imaging pattern and
treatment assignment on the favorable primary outcome effect
(p= 0.14). There was a relatively low rate of substantial revascu-
larization in the embolectomy group, which could be related to
the use of first-generation embolectomy devices. Long delays up
to 5.3± 1.6 h from imaging to embolectomy and the heterogene-
ity of imaging approaches based on the use of both MRI and CT
were additional factors that might have diluted treatment effect.
A favorable penumbral pattern beyond 3 h may be a signature of
more vigorous collateral vessels and therefore of greater tolerance
to occlusion, increased likelihood of spontaneous recanalization
and good outcome (66). The MR Rescue trial did not show a
differential benefit among patients who underwent embolectomy
between those with a favorable penumbral pattern as compared
with those with a non-penumbral patttern. These findings differ
from those in the DEFUSE 2 trial where patients had a shorter
time until treatment and smaller predicted infarct cores.
IMS-III and SYNTHESIS did not target the best patient pop-
ulations to achieve positive results. These trials failed to prove
the superiority of endovascular treatment because vascular sta-
tus was not systematically evaluated, salvageable brain tissue was
presumably small or not present in many patients, time from base-
line neuroimaging to recanalization was too long and the devices
used have been rendered obsolete by stent-retrievers. Despite these
limitations, these trials have demonstrated that endovascular treat-
ment is safe and provide data that could be relevant in the design
of future trials aiming to prove the applicability of this treatment
in certain patients (67–69).
Concerning reperfusion scales, the Thrombolysis in Myocar-
dial Infarction Scale (TIMI), originally constructed to measure
myocardial reperfusion, has been widely adopted for use in cere-
bral circulation (Table 3) (70). The TICI Scale was originally
proposed in a position statement that attempted to standardize
clinical trial design and reporting for intra-arterial therapy. The
TICI scale specifically addresses the extent of tissue reperfusion, as
represented by the capillary blush on digital subtraction angiogra-
phy (71). The original TICI system defined TICI 2b as restoration
of more than two thirds of the target downstream territory. This is
in contrast to the subsequent modified version mTICI (modified
treatment in cerebral ischemia introduced by the IMS investi-
gators, which uses a threshold of more than half of the target
downstream territory (22, 23) (Table 4). In a comparative study
of TIMI and mTICI, the c-statistic for predicting 90-day good
outcome (mRS 0–2) was significantly higher for mTICI vs. TIMI
(0.74 vs. 0.68; p< 0.0001) (72). Currently, the target angiographic
endpoint for assigning technical success should be mTICI 2b or
higher (73).
In summary, we have learned from these trials that endovascu-
lar treatment after tPA is as safe as endovascular treatment alone
and that stent-retrievers achieve faster arterial recanalization in
Table 3 |Thrombolysis in Myocardial Ischemia Scale.
TIMI grades Definitions
Grade 0 Absence of any antegrade flow beyond the target occlusion
(no perfusion)
Grade 1 Any faint antegrade flow beyond the target occlusion, with
incomplete filling of the distal branches (penetration without
perfusion)
Grade 2 Delayed or sluggish antegrade flow with complete filling of
the distal M2 branches flow (partial perfusion)
Grade 3 Normal flow that fills all distal branches, including M3 and
M4 (complete perfusion)
TIMI indicates thrombolysis in myocardial ischemia.
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Table 4 | Modified treatment in Cerebral Ischemia Scale.
mTICI grades Definitions
Grade 0 No perfusion
Grade 1 Antegrade reperfusion past the initial occlusion, but
limited distal branch filling with little or slow distal
reperfusion
Grade 2a Antegrade reperfusion of less than half of the occluded
target artery previously ischemic territory (e.g., in one
major division of the MCA and its territory)
Grade 2b Antegrade reperfusion of more than half of the previously
occluded target artery ischemic territory (e.g., in two
major divisions of the MCA and their territories)
Grade 3 Complete antegrade reperfusion of the previously
occluded target artery ischemic territory, with absence of
visualized occlusion in all distal branches
MCA indicates middle cerebral artery; and mTICI is modified treatment in cerebral
ischemia scale.
acute ischemic stroke. We also have learned that while endovas-
cular therapy may only be useful for selected patients, who we do
not yet know how to select optimally, it has not proven useful for
stroke patients in general. Thus, it is essential to use the lessons of
these trials results in order to design new trials.
HOW CANWE ADVANCE?
Randomized controlled trials (RCTs) need to answer a set of open
questions. It is very important that they all move together in the
same direction and randomize all the eligible patients in order to
avoid selection bias. We may make progress through the challenges
that a knowledge of previous studies affords us.
Concerning the endovascular treatment arm of the trials
Recent neutral RCTs of endovascular therapy have shown that the
technological improvement of devices moves faster than patient
recruitment. Consequently, ongoing and future trials should be
inclusive and allow the use of any approved device that interven-
tionalists believe will yield the best results. The main problem with
this approach is that different devices or techniques may have dif-
ferent complications and efficacy rates, so merging devices may
potentially affect the interpretation of the endovascular arm of
the trials.
“Time is brain,” so any time delay in treatment administra-
tion must be minimized. As in any trial, endovascular stroke
trials require mandatory steps that are time-consuming such as
obtaining informed consent, checking inclusion, and exclusion
criteria and randomization. Therefore, it is important to reduce
time delays affecting the endovascular treatment arm through
randomization in the angiosuite with team activated, and with
a precisely definined standard metric for door-to-groin-puncture
time (74). Moreover, these trials might benefit from close coopera-
tion between the different participating centers in order to shorten
the delay caused by the transfer of patients.
Centers with best and fastest endovascular stroke treatment
facilities should be preferentially considered for such trials, and it
is important to carry out extensive preparation and continued edu-
cation and monitoring of all participating centers to ensure their
ability to randomize patients appropriately and achieve as short a
time as possible from imaging to reperfusion. Problems generated
by this approach are slow recruitment and lack of generalizability
of the trial results. Regarding standarization of the procedure, in
general, precise metrics need to be defined and monitored. It is
also important to have a set of pre-defined actions that should
be taken when the center being monitored does not fullfill the
required metrics.
There is consensus that, if possible, general anesthesia should
be avoided due to the fact that it is associated with worse functional
outcome and time delays (75).
Concerning imaging-based patient selection
There is no doubt that CT or MR imaging including the study
of the ischemic core and vessel occlusion is highly recommended
for endovascular patient selection. Collateral status has emerged
as critical for brain tissue survival until the clot is lysed and
sufficient anterograde perfusion is achieved, so an emerging chal-
lenge is obtaining additional information about collateral status
in endovascular trials (76–79). The Safety and Efficacy of Neu-
roflo Technology in Ischemic Stroke (SENTIS) trial was the first
randomized controlled trial to test the effect of a device to poten-
tially increase collateral blood flow to the brain (80). Although the
trial failed to meet the pre-specified primary efficacy endpoint,
the safety of the treatment was confirmed. Also, it showed that
patients with favorable vascular profiles in multimodal imaging
were most likely to benefit from this approach, mainly in the older
cohort of patients above 70 years of age (81). Analysis of the IMS III
trial results showed that robust angiographic collateral grade was
a significant predictor of good clinical outcome at 90 days. Sim-
ilar findings were seen in the SWIFT and TREVO2 trials. Thus,
it appears that collateral evaluation may be used to enhance the
approach to treat stroke and to refine future trial designs.
Concerning trial design
Probably the most important problem for the internal valid-
ity of a trial is when a substantial number of eligible patients
are presumibily treated outside of the trial. A powerful poten-
tial challenge would be to use government-mandated and audited
population-based databases of reperfusion therapies (82).
The main outcome based on the degree of functional dis-
ability is usually measured by the modified Rankin Score. This
score is a monotonic scale, except for the similarity between the
two most severe levels, 5 and 6 (83). As a consequence, a “shift”
analysis is more likely to find relevant differences in the modified
Rankin Score distribution between the two groups in a study than
a pre-specified threshold.
Currently, there are two major research questions
Is bridging therapy more effective than intravenous treatment in
patients with large-vessel occlusions in the anterior circulation?
Bridging therapy is safe but the question about whether it is more
effective than intravenous treatment remains open. Trials should
compare intravenous thrombolytic treatment as the control group
vs. intravenous thrombolysis plus mechanical thrombectomy as
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the experimental group. A trial comparing intravenous tPA vs.
mechanical thrombectomy in patients eligible for intravenous
thrombolysis could be a reasonable design once combined therapy
had been demonstrated to be superior to intravenous tPA.
Bridging therapy might be better than isolated intravenous tPA
in patients with proximal vessel occlusions. Trials comparing the
two treatment arms should include a baseline imaging vessel study.
A rather small proportion of patients in IMS III trial had proximal
occlusions. In this subgroup of patients combined treatment was
superior to intravenous tPA alone (84).
Is mechanical thrombectomy more effective than best medical
treatment in patients ineligible for intravenous thrombolysis?
Trials comparing endovascular treatment vs. best medical treat-
ment without administration of intravenous tPA may be more
difficult to carry out since many physicians may consider this
design unethical despite the fact that there are no RCTs demon-
strating the superiority of endovascular treatment in these situa-
tions.
There are several reasons for considering a patient ineligible for
intravenous thrombolysis, which can be divided into two different
profiles: those that derive from limits in the time window and those
that are associated with a higher risk of bleeding such as abnormal
hemostasis, anticoagulant treatment with an INR higher than 1.7
or recent (last two months) major surgery. These two groups may
have different safety profiles.
Patients arriving for treatment beyond 4.5 h are ineligible for
intravenous rt-PA. Endovascular treatment, mainly mechanical
thrombectomy, could be a good alternative treatment but cur-
rently there are no results from RCTs answering this open question.
In these longer time windows, good clinical outcome is associ-
ated with the presence of salvageable brain tissue, which mainly
depends on collateral flow status, which in turn may be estimated
by means of different imaging modalities, e.g., ASPECTS score, CT
angiography source imaging, CT perfusion, or multimodal MRI. A
retrospective analysis of one multicentre prospective cohort study
(DEFUSE 2) suggested that MRI could diagnose patients who did
or did not benefit from the treatment before interventional treat-
ment up to 12 h from symptom onset. These data need to be
confirmed in a randomized study but suggest that the time window
for treatment can be extended in some patients. In the Penum-
bra pivotal stroke trial (27), recanalization benefited patients with
a favorable image on the baseline CT scan as indicated by an
ASPECTS score >7. In fact, some patients are able to maintain
a penumbra for as long as 48 h (79, 85) and thus may still benefit
from mechanical thrombectomy. Natarajan et al. (86) published a
study showing the benefit with safety of endovascular therapy in
patients after 8 h from symptoms onset and wake-up strokes. For
these reasons, the use of imaging selection criteria is essential in
these studies.
Focusing on the other group of patients, out of the three
causes, patients with illness producing abnormal hemostasis are
anecdotal. More common are patients undergoing oral anticoag-
ulant treatment, mostly with anti-vitamin K drugs. In these cases,
although only short series are reported in the literature, the results
are quite good (87). Patients with recent surgery can not receive
endovenous tPA due to the risk of bleeding. These patients can
suffer a stroke mediated by a procoagulant state and sometimes
favored by the withdrawal of antiplatelets or anticoagulants. Data
from several case series have been published showing that the
endovascular approach is safe and effective (88).
WHERE ARE WE HEADED?
Several prospective and randomized clinical trials of mechani-
cal thrombectomy are now enrolling patients to overcome the
limitations of previous trials.
The main ongoing randomized clinical trials for mechanical
thrombectomy are THRACE, PISTE, MRCLEAN, and REVASCAT
in Europe, SWIFT-PRIME in the US, and THERAPY and ESCAPE
in Canada (Table 5).
Trial and cost-effectiveness evaluation of intra-arterial
thrombectomy in acute ischemic stroke (THRACE) (ClinicalTri-
als.gov Identifier: NCT01062698) is a multicentre randomized
controlled trial with the primary objective of determining whether
a combined approach of intravenous thrombolysis (IV) plus
mechanical thrombectomy (Merci, Penumbra, Catch, and Soli-
taire) is superior to IV thrombolysis alone within the 3 h of onset of
symptoms in patients with occlusion of proximal cerebral arteries
and a NIHSS ≥10. The secondary aim is to determine the cost-
effectiveness of this procedure compared to the standard treatment
(IV thrombolysis). Projected sample size is 480 patients. At the
present time, the recruitment criteria for this study is unknown
because the information has not been verified.
Pragmatic Ischemic Stroke Thrombectomy Evaluation [(PISTE);
A randomized controlled clinical trial of adjunctive mechani-
cal thrombectomy compared with intravenous thrombolysis in
patients with acute ischemic stroke due to an occluded major
intracranial vessel] (ClinicalTrials.gov Identifier: NCT01745692)
is a randomized controlled trial testing whether mechanical
thrombectomy improves functional outcome in patients with large
artery occlusion on top of IV thrombolysis. The projected sam-
ple size is 800 subjects. This study is not yet open for participant
recruitment.
Multicenter Randomized Clinical trial of Endovascular treat-
ment for Acute ischemic stroke in the Netherlands (MR CLEAN)
(ISRCTN10888758) is a pragmatic phase III multicentre random-
ized clinical trial with blinded outcome assessment. The primary
objective of this study is to estimate the effect of endovascu-
lar treatment on overall functional outcome after acute ischemic
stroke of less than 6-h duration in patients with a symptomatic
intracranial anterior circulation occlusion. Intervention arm con-
sist of endovascular treatment by means of the local application
of rt-PA or urokinase by guided micro-catheter, and/or mechan-
ical thrombectomy, by means of a retraction device, aspiration
device, or retrievable stent. The intervention arm could be for
patients who have been treated in successfully with IV thrombol-
ysis, patients who can be treated within 6 h but do not meet the
time window requirements for IV thrombolysis, and patients with
contraindications for IV or intra-arterial thrombolytic treatment
(thrombectomy only). The control arm consists of regular treat-
ment according to current national clinical guidelines, including
intravenous t-PA within the first 4.5 h after symptom onset. The
projected sample size is 500 subjects. Recruitment has recently
finished.
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Endovascular Revascularization With Solitaire Device vs. Best
Medical Therapy [(REVASCAT) in anterior circulation stroke
within 8 h] (ClinicalTrials.gov Identifier: NCT01692379) is a
prospective, multicentre randomized trial seeking to establish
whether subjects meeting the main inclusion criteria of age 18–85,
baseline NIHSS ≥6, evidence of TICA or proximal (M1) MCA,
ASPECTS score of ≥7 on NCCT or ≥6 on diffusion-weighted
MRI, ineligible for or with persistent occlusion after IV alteplase
and treated within 8 h from symptom onset have higher rates
of favorable outcome when treated with the Solitaire embolec-
tomy device compared to standard medical therapy alone. The
primary endpoint, based on intention-to-treat criteria, is the dis-
tribution of mRS scores at 90 days. Maximum sample size is 690
patients with three previous specified interim looks. Randomiza-
tion is performed under a minimization process using age, baseline
NIHSS, therapeutic window, occlusion location, and investiga-
tional center. Secondary endpoints are infarct volume evaluated
on CT at 24 h, dramatic early favorable response, defined as NIHSS
of 0–2, or NIHSS improvement ≥8 points at 24 h and successful
recanalization in the Solitaire arm according to the TICI classifi-
cation defined as TICI 2b or 3. Safety variables are mortality at
90 days, symptomatic intracranial hemorrhage rates at 24 h, and
procedure-related complications.
Endovascular treatment for small core and proximal occlu-
sion ischemic stroke (ESCAPE) (ClinicalTrials.gov Identifier:
NCT01778335) is a phase III, randomized,open-label with blinded
outcome evaluation, controlled, parallel-group trial. The primary
objectives of this study are to show that rapid endovascular revas-
cularization amongst radiologically selected (small core/proximal
occlusion) patients with ischemic stroke results in improved out-
come compared to patients treated in clinical routine. Eligible
patients will be enrolled within 12 h of last seen normal with a
baseline NIHSS >5 at the time of randomization. There must be
a confirmed symptomatic intracranial occlusion, based on single
phase, multiphase, or dynamic CTA, at one or more of the fol-
lowing locations: carotid T/L, M1 MCA, or M1-MCA equivalent
(2 or more M2-MCAs). All patients will receive the best standard
of medical care according to modern acute stroke care guidelines
(IV alteplase if <4.5 h from symptoms onset). Intervention arm
consist of endovascular treatment by means of retrievable stent
plus other endovascular treatment at discretion of interventional-
ist. This study consists of one 90-day study period for each subject.
This study is in the process of enrolling participants.
Solitaire FR as primary treatment for acute ischemic stroke
(SWIFT-PRIME) (ClinicalTrials.gov Identifier: NCT016557461).
It is a multicentre, two-arm, prospective, randomized, open,
blinded-endpoint study comparing functional outcomes (defined
by mRS) in acute ischemic stroke patients who are treated with
either intravenous tPA alone or intravenous in combination with
Solitaire mechanical thrombectomy intervention. The sample size
is up to 833 patients. Key inclusion criteria are age 18–85, pre-
stroke functional independence, NIHSS 8–29, start of intravenous
tPA within 4.5 h of onset, M1 MCA, or intracranial ICA occlu-
sion on CTA or MRA, and target mismatch penumbral profile on
multimodal CT or MR imaging. Patients allocated to the device
arm will undergo mechanical thrombectomy with up to three
passes of the Solitaire stent-retriever. Rapid procedure start is
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emphasized, within 90 min after penumbral imaging. The primary
endpoint is degree of global disability at 90 days. Secondary clinical
endpoints are all-cause mortality, functional independence (mRS
0–2) at 90 days, and early neurologic deficit improvement (NIHSS
change at 24 h); secondary technical efficacy endpoints include
revascularization/reperfusion at 24 h and infarct volume at 24 h.
THERAPY trial (A Prospective, Randomized Trial to Assess the
Role of Mechanical Thrombectomy as Adjunctive Treatment to
IV rtPA) (ClinicalTrials.gov Identifier: NCT01429350). THERAPY
is a prospective, multicentre, randomized, concurrent controlled
study. Patients from 18 to 85 years old (n= 582) presenting with
acute ischemic stroke symptoms, an NIHSS score of at least 8 or
aphasic, and eligible for intravenous rtPA with evidence of a clot
at least 8 mm long in the anterior circulation from reconstructed
thin-sliced non-enhanced CT are randomly assigned 1:1 to intra-
venous rtPA therapy alone or combined intravenous rtPA therapy
and adjunctive treatment with the Penumbra System. The primary
endpoints are good 90-day functional outcome and incidence of
serious adverse events. Secondary endpoints include good neuro-
logical and functional outcomes at discharge and 30 days, as well
as the incidence of ICH.
CONCLUSION
Currently, intravenous rt-PA is the only approved treatment for
acute ischemic stroke within 4.5 h from symptoms onset. How-
ever, many patients are still left undertreated, mainly due to the
short time window and other contraindications for intravenous
tPA. Several strategies have been developed to increase the num-
ber of treated patients. In the field of acute diagnosis, the use of
multimodal neuroimaging allows physicians to evaluate not only
the ischemic core but also the vessel pattern and collateral sta-
tus. Concerning treatment, several molecules are being tested in
randomized clinical trials with extended time windows. In this
context, endovascular treatment is a promising technique that
allows physicians not only to treat patients in extended time win-
dows but also to treat patients in whom intravenous tPA has failed.
Regarding endovascular treatments, a new era has emerged with
new devices called stent-retrievers that have demonstrated higher
rates of recanalization and clear superiority over previous devices
employed in RCTs. However, the failure of recent endovascular
trials to demonstrate the benefit of an endovascular approach
over intravenous tPA has forced new trial designs. Several ongo-
ing randomized clinical trials are now investigating two main
research questions: the first one is whether bridging therapy is
more effective than intravenous treatment alone and the second
one is whether mechanical thrombectomy is more effective than
the best medical treatment in patients ineligible for intravenous
thrombolysis. We would therefore argue that the most advisable
strategy to make progress in the field of reperfusion therapies for
acute ischemic stroke is to randomize patients in well-designed
clinical trials.
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